All lobbying filings

THE MCMANUS GROUP

Lobbying for VIVEX BIOLOGICS · Biologics Company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Florida · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 3

HR 5768
Skin Substitute Access and Payment Reform Act
S 2561
Skin Substitute Access and Payment Reform Act of 2025
HR 6852
Advanced Wound Care and Regenerative Medicine Access and Reform Act

Lobbying activity 2

Health Issues

Education on FDA regulation of Human Cellular Tissue Products (HCTPs).

Medicare/Medicaid

Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.